Halozyme Therapeutics Inc 2023 SR
The report highlights Halozyme's ESG progress for 2023, focusing on its mission to improve patient experiences through its ENHANZE technology. Key achievements include relocating to a more energy-efficient headquarters in San Diego, achieving a 50% female executive team, and raising over $50,000 for St. Jude Children's Research Hospital. The company aligns its reporting with SASB and TCFD frameworks and has set a goal to achieve NetZero energy usage at its headquarters by 2030. Additionally, Halozyme demonstrated strong employee engagement with an 81% survey participation rate and a voluntary turnover rate consistently below the industry average.
Company: Halozyme Therapeutics Inc
Sector: Health Care
Country: United States
Year: 2023
Type: SR
Pages: 37
Halozyme Therapeutics Inc
ESG Report
The report highlights Halozyme's ESG progress for 2023, focusing on its mission to improve patient experiences through its ENHANZE technology. Key achievements include relocating to a more energy-efficient headquarters in San Diego, achieving a 50% female executive team, and raising over $50,000 for St. Jude Children's Research Hospital. The company aligns its reporting with SASB and TCFD frameworks and has set a goal to achieve NetZero energy usage at its headquarters by 2030. Additionally, Halozyme demonstrated strong employee engagement with an 81% survey participation rate and a voluntary turnover rate consistently below the industry average.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Energy Consumption
Renewable Energy
Water Consumption
Women in Management
Workplace Fatalities
Employees